Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Atsushi Sakuraba

TitleAssistant Professor
InstitutionUniversity of Chicago
DepartmentMedicine-Gastroenterology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Yamada A, Wang J, Komaki Y, Komaki F, Micic D, Sakuraba A. Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents. Aliment Pharmacol Ther. 2019 Aug; 50(4):373-385. PMID: 31309607.
      View in: PubMed
    2. Komaki Y, Komaki F, Micic D, Ido A, Sakuraba A. Risk of Fractures in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2019 Jul; 53(6):441-448. PMID: 29672437.
      View in: PubMed
    3. Israel A, Christensen B, El Jurdi K, Rai V, Ollech J, Cohen RD, Sakuraba A, Dalal S, Rubin DT. Follow-Up of Ulcerative Colitis Patients Who Have Achieved Histological Normalization. Clin Gastroenterol Hepatol. 2019 Jun 20. PMID: 31228567.
      View in: PubMed
    4. Ollech JE, Rubin DT, Glick L, Weisshof R, El Jurdi K, Israel A, Krugliak Cleveland N, Hyman N, Sakuraba A, Pekow J, Cohen RD, Dalal SR. Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. Dig Dis Sci. 2019 Jun 11. PMID: 31187322.
      View in: PubMed
    5. Wang Y, Wang J, Pekow J, Dalal S, Cohen RD, Ollech J, Israel A, Shogan BD, Micic D, Cannon L, Umanskiy K, Hurst R, Hyman N, Rubin DT, Sakuraba A. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Jun 06. PMID: 31169926.
      View in: PubMed
    6. Weisshof R, Aharoni Golan M, Sossenheimer PH, El Jurdi K, Ollech JE, Pekow J, Cohen RD, Sakuraba A, Dalal S, Rubin DT. Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Dig Dis Sci. 2019 Jul; 64(7):1945-1951. PMID: 30734234.
      View in: PubMed
    7. Ollech JE, Aharoni-Golan M, Weisshof R, Normatov I, Sapp AR, Kalakonda A, Israel A, Glick LR, Karrison T, Dalal SR, Sakuraba A, Cohen RD, Rubin DT, Pekow J. Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. Gastrointest Endosc. 2019 08; 90(2):269-275. PMID: 30738034.
      View in: PubMed
    8. Weisshof R, Ollech JE, Jurdi KE, Yvellez OV, Cohen RD, Sakuraba A, Dalal S, Pekow J, Rubin DT. Ciclosporin therapy after infliximab failure in hospitalized patients with acute severe colitis is effective and safe. J Crohns Colitis. 2019 Feb 06. PMID: 30726894.
      View in: PubMed
    9. Micic D, Komaki Y, Alavanja A, Rubin DT, Sakuraba A. Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies. J Clin Gastroenterol. 2019 Jan; 53(1):e1-e11. PMID: 28737645.
      View in: PubMed
    10. Coronel E, Cazacu IM, Sakuraba A, Luzuriaga Chavez AA, Uberoi A, Geng Y, Tomizawa Y, Saftoiu A, Shin EJ, Taniguchi CM, Koong AC, Herman JM, Bhutani MS. EUS-guided fiducial placement for GI malignancies: a systematic review and meta-analysis. Gastrointest Endosc. 2019 04; 89(4):659-670.e18. PMID: 30445001.
      View in: PubMed
    11. Micic D, Yarur A, Gonsalves A, Rao VL, Broadaway S, Cohen R, Dalal S, Gaetano JN, Glick LR, Hirsch A, Pekow J, Sakuraba A, Walk ST, Rubin DT. Correction to: Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 10; 63(10):2815. PMID: 30136047.
      View in: PubMed
    12. Komaki Y, Komaki F, Micic D, Ido A, Sakuraba A. Risk of Colorectal Cancer in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2018 10; 52(9):796-804. PMID: 28723862.
      View in: PubMed
    13. Anyane-Yeboa A, Yamada A, Haider H, Wang Y, Komaki Y, Komaki F, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A. A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. Aliment Pharmacol Ther. 2018 11; 48(9):933-940. PMID: 30126019.
      View in: PubMed
    14. Melmed GY, Dubinsky MC, Rubin DT, Fleisher M, Pasha SF, Sakuraba A, Tiongco F, Shafran I, Fernandez-Urien I, Rosa B, Papageorgiou NP, Leighton JA. Utility of video capsule endoscopy for longitudinal monitoring of Crohn's disease activity in the small bowel: a prospective study. Gastrointest Endosc. 2018 12; 88(6):947-955.e2. PMID: 30086261.
      View in: PubMed
    15. Tomizawa Y, Melek J, Komaki Y, Kavitt RT, Sakuraba A. Efficacy of Pharmacologic Therapy for Eosinophilic Esophagitis: A Systematic Review and Network Meta-Analysis. J Clin Gastroenterol. 2018 08; 52(7):596-606. PMID: 28787360.
      View in: PubMed
    16. Yamada A, Komaki Y, Komaki F, Micic D, Zullow S, Sakuraba A. Gastrointestinal cancers in patients with cystic fibrosis - Authors' reply. Lancet Oncol. 2018 08; 19(8):e369. PMID: 30102219.
      View in: PubMed
    17. Wang J, Bhatia A, Krugliak Cleveland N, Gupta N, Dalal S, Rubin DT, Sakuraba A. Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab Infusion. ACG Case Rep J. 2018; 5:e56. PMID: 30105273.
      View in: PubMed
    18. Yamada A, Komaki Y, Komaki F, Micic D, Zullow S, Sakuraba A. Gastrointestinal cancer risk in cystic fibrosis: more exploration is needed - Authors' reply. Lancet Oncol. 2018 07; 19(7):e333. PMID: 30084376.
      View in: PubMed
    19. Yamada A, Komaki Y, Komaki F, Micic D, Zullow S, Sakuraba A. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. Lancet Oncol. 2018 06; 19(6):758-767. PMID: 29706374.
      View in: PubMed
    20. Yamada A, Komaki Y, Patel N, Komaki F, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):502-509. PMID: 29462385.
      View in: PubMed
    21. Tomizawa Y, Tanaka A, Kitahara H, Sakuraba A, Uriel N, Jeevanandam V, Ota T. Preoperative Right-Sided Cardiac Congestion Is Associated with Gastrointestinal Bleeding in Patients with Continuous-Flow Left Ventricular Assist Devices. Dig Dis Sci. 2018 Jun; 63(6):1518-1524. PMID: 29417325.
      View in: PubMed
    22. Micic D, Yarur A, Gonsalves A, Rao VL, Broadaway S, Cohen R, Dalal S, Gaetano JN, Glick LR, Hirsch A, Pekow J, Sakuraba A, Walk ST, Rubin DT. Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 04; 63(4):1016-1024. PMID: 29417331.
      View in: PubMed
    23. Komaki Y, Yamada A, Komaki F, Sakuraba A. Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients-authors' reply. Aliment Pharmacol Ther. 2017 11; 46(9):905-906. PMID: 29023885.
      View in: PubMed
    24. Komaki Y, Komaki F, Yamada A, Micic D, Ido A, Sakuraba A. Meta-Analysis of the Risk of Immune-Related Adverse Events With Anticytotoxic T-Lymphocyte-Associated Antigen 4 and Antiprogrammed Death 1 Therapies. Clin Pharmacol Ther. 2018 02; 103(2):318-331. PMID: 28118483.
      View in: PubMed
    25. Micic D, Gaetano JN, Rubin JN, Cohen RD, Sakuraba A, Rubin DT, Pekow J. Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. PLoS One. 2017; 12(8):e0182900. PMID: 28837634.
      View in: PubMed
    26. Yamada A, Komaki Y, Patel N, Komaki F, Aelvoet AS, Tran AL, Pekow J, Dalal S, Cohen RD, Cannon L, Umanskiy K, Smith R, Hurst R, Hyman N, Rubin DT, Sakuraba A. Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. Am J Gastroenterol. 2017 Sep; 112(9):1423-1429. PMID: 28719595.
      View in: PubMed
    27. Komaki Y, Komaki F, Micic D, Yamada A, Suzuki Y, Sakuraba A. Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta-analysis. J Gastroenterol Hepatol. 2017 Jun; 32(6):1143-1151. PMID: 27957761.
      View in: PubMed
    28. Ananthakrishnan AN, Sakuraba A, Barnes EL, Pekow J, Raffals L, Long MD, Sandler RS. The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. Aliment Pharmacol Ther. 2017 07; 46(2):162-168. PMID: 28470787.
      View in: PubMed
    29. Komaki Y, Yamada A, Komaki F, Micic D, Ido A, Sakuraba A. Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply. Aliment Pharmacol Ther. 2017 05; 45(10):1372. PMID: 28417494.
      View in: PubMed
    30. Komaki Y, Yamada A, Komaki F, Micic D, Ido A, Sakuraba A. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-a agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017 04; 45(8):1043-1057. PMID: 28239873.
      View in: PubMed
    31. Komaki Y, Yamada A, Komaki F, Kudaravalli P, Micic D, Ido A, Sakuraba A. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-a agents in rheumatic diseases; A systematic review and meta-analysis. J Autoimmun. 2017 May; 79:4-16. PMID: 28209290.
      View in: PubMed
    32. Sofia MA, Sakuraba A, Rubin DT. Two Complex Cases of Hermansky-Pudlak Syndrome Highlight a Potential Biologic Explanation for an Associated Crohn's Disease Phenotype. ACG Case Rep J. 2017; 4:e14. PMID: 28144619.
      View in: PubMed
    33. Komaki Y, Komaki F, Micic D, Ido A, Sakuraba A. Risk of colorectal cancer in chronic liver diseases: a systematic review and meta-analysis. Gastrointest Endosc. 2017 Jul; 86(1):93-104.e5. PMID: 28011280.
      View in: PubMed
    34. Komaki F, Komaki Y, Micic D, Ido A, Sakuraba A. Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-a use in females with immune mediated diseases; a systematic review and meta-analysis. J Autoimmun. 2017 01; 76:38-52. PMID: 27913060.
      View in: PubMed
    35. Meckel K, Li YC, Lim J, Kocherginsky M, Weber C, Almoghrabi A, Chen X, Kaboff A, Sadiq F, Hanauer SB, Cohen RD, Kwon J, Rubin DT, Hanan I, Sakuraba A, Yen E, Bissonnette M, Pekow J. Serum 25-hydroxyvitamin D concentration is inversely associated with mucosal inflammation in patients with ulcerative colitis. Am J Clin Nutr. 2016 07; 104(1):113-20. PMID: 27281309.
      View in: PubMed
    36. Saad AM, Czul F, Sakuraba A, Rubin DT, Cohen RD. Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease. Inflamm Bowel Dis. 2016 May; 22(5):1027-31. PMID: 26919459.
      View in: PubMed
    37. Sandborn WJ, Sakuraba A, Wang A, Macaulay D, Reichmann W, Wang S, Chao J, Skup M. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. Curr Med Res Opin. 2016 07; 32(7):1233-41. PMID: 26986449.
      View in: PubMed
    38. Komaki Y, Komaki F, Sakuraba A, Cohen R. Approach to Optimize Anti-TNF-a Therapy in Patients With IBD. Curr Treat Options Gastroenterol. 2016 Mar; 14(1):83-90. PMID: 26872815.
      View in: PubMed
    39. Sakuraba A, Armuzzi A, Keyashian K, Naganuma M. Novel Topics in Inflammatory Bowel Disease. Biomed Res Int. 2016; 2016:8958751. PMID: 27006952.
      View in: PubMed
    40. Bellaguarda E, Sakuraba A. Reply. Clin Gastroenterol Hepatol. 2016 May; 14(5):776-7. PMID: 26853161.
      View in: PubMed
    41. Yokoyama Y, Futagami M, Watanabe J, Sakuraba A, Nagasawa K, Maruyama H, Sato S. The advantages of incorporating liquid-based cytology (TACAS™) in mass screening for cervical cancer. Hum Cell. 2016 Apr; 29(2):83-90. PMID: 26739336.
      View in: PubMed
    42. Komaki Y, Komaki F, Ido A, Sakuraba A. Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. J Crohns Colitis. 2016 Apr; 10(4):484-94. PMID: 26645641.
      View in: PubMed
    43. Coronel E, Singh A, Sakuraba A. The "Moonsault" maneuver: retroflexed ileocecal valve insertion. Gastrointest Endosc. 2016 Mar; 83(3):663. PMID: 26432941.
      View in: PubMed
    44. Bellaguarda E, Keyashian K, Pekow J, Rubin DT, Cohen RD, Sakuraba A. Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. Clin Gastroenterol Hepatol. 2015 Nov; 13(11):1919-25. PMID: 26001336.
      View in: PubMed
    45. Sakuraba A, Okamoto S, Matsuoka K, Sato T, Naganuma M, Hisamatsu T, Iwao Y, Ogata H, Kanai T, Hibi T. Combination therapy with infliximab and thiopurine compared to infliximab monotherapy in maintaining remission of postoperative Crohn's disease. Digestion. 2015; 91(3):233-8. PMID: 25823572.
      View in: PubMed
    46. Tomizawa Y, Sakuraba A, Pekow J. Parastomal Variceal Bleeding Attributed to Obstructive Pathology Successfully Treated by Percutaneous Variceal Embolization. ACG Case Rep J. 2014 Jul; 1(4):217-9. PMID: 26157881.
      View in: PubMed
    47. Hayes MJ, Stein AC, Sakuraba A. Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis. J Gastroenterol Hepatol. 2014 Jun; 29(6):1177-85. PMID: 24955449.
      View in: PubMed
    48. Sakuraba A, Iwao Y, Matsuoka K, Naganuma M, Ogata H, Kanai T, Hibi T. Endoscopic and pathologic changes of the upper gastrointestinal tract in Crohn's disease. Biomed Res Int. 2014; 2014:610767. PMID: 24672792.
      View in: PubMed
    49. Sakuraba A, Annunziata ML, Cohen RD, Hanauer SB, Rubin DT. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis. 2013 Nov; 19(12):2577-83. PMID: 24132161.
      View in: PubMed
    50. Melek J, Sakuraba A. Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: a meta-analysis and systematic review. Clin Gastroenterol Hepatol. 2014 Jan; 12(1):32-44.e5. PMID: 23981521.
      View in: PubMed
    51. Watanabe C, Komoto S, Hokari R, Kurihara C, Okada Y, Hozumi H, Higashiyama M, Sakuraba A, Tomita K, Tsuzuki Y, Kawaguchi A, Nagao S, Ogata S, Miura S. Prevalence of serum celiac antibody in patients with IBD in Japan. J Gastroenterol. 2014 May; 49(5):825-34. PMID: 23754511.
      View in: PubMed
    52. Naganuma M, Sakuraba A, Hibi T. Ulcerative colitis: prevention of relapse. Expert Rev Gastroenterol Hepatol. 2013 May; 7(4):341-51. PMID: 23639092.
      View in: PubMed
    53. Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Sato N, Yoshinari T, Motegi K, Kinouchi Y, Takazoe M, Suzuki Y, Matsumoto T, Kawakami K, Matsumoto T, Hirata I, Tanaka S, Ashida T, Matsui T. C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease. J Gastroenterol. 2014 Feb; 49(2):254-62. PMID: 23604570.
      View in: PubMed
    54. Sakuraba A, Keyashian K, Correia C, Melek J, Cohen RD, Hanauer SB, Rubin DT. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6. PMID: 23429449.
      View in: PubMed
    55. Keyashian K, Annunziata ML, Sakuraba A, Hanauer S. Management of inflammatory bowel disease: past, present and future. Expert Rev Clin Immunol. 2012 May; 8(4):303-5. PMID: 22607175.
      View in: PubMed
    56. Sakuraba A, Sato T, Morohoshi Y, Matsuoka K, Okamoto S, Inoue N, Takaishi H, Ogata H, Iwao Y, Hibi T. Intermittent granulocyte and monocyte apheresis versus mercaptopurine for maintaining remission of ulcerative colitis: a pilot study. Ther Apher Dial. 2012 Jun; 16(3):213-8. PMID: 22607563.
      View in: PubMed
    57. Sakuraba A, Sato T, Matsukawa H, Okamoto S, Takaishi H, Ogata H, Iwao Y, Hibi T. The use of infliximab in the prevention of postsurgical recurrence in polysurgery Crohn's disease patients: a pilot open-labeled prospective study. Int J Colorectal Dis. 2012 Jul; 27(7):947-52. PMID: 22231620.
      View in: PubMed
    58. Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Motegi K, Kinouchi Y, Takazoe M, Suzuki Y, Matsumoto T, Kawakami K, Matsumoto T, Hirata I, Tanaka S, Ashida T, Matsui T. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease. Inflamm Bowel Dis. 2012 Aug; 18(8):1480-7. PMID: 21987418.
      View in: PubMed
    59. Hoentjen F, Sakuraba A, Hanauer S. Update on the management of ulcerative colitis. Curr Gastroenterol Rep. 2011 Oct; 13(5):475-85. PMID: 21789495.
      View in: PubMed
    60. Sakuraba A, Motoya S, Watanabe K, Nishishita M, Kanke K, Matsui T, Suzuki Y, Oshima T, Kunisaki R, Matsumoto T, Hanai H, Fukunaga K, Yoshimura N, Chiba T, Funakoshi S, Aoyama N, Andoh A, Nakase H, Mizuta Y, Suzuki R, Akamatsu T, Iizuka M, Ashida T, Hibi T. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009 Dec; 104(12):2990-5. PMID: 19724269.
      View in: PubMed
    61. Sakuraba A, Sato T, Kamada N, Kitazume M, Sugita A, Hibi T. Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease. Gastroenterology. 2009 Nov; 137(5):1736-45. PMID: 19632232.
      View in: PubMed
    62. Iwakami Y, Sakuraba A, Sato T, Takada Y, Izumiya M, Ichikawa H, Hibi T. Granulocyte and monocyte adsorption apheresis therapy modulates monocyte-derived dendritic cell function in patients with ulcerative colitis. Ther Apher Dial. 2009 Apr; 13(2):138-46. PMID: 19379153.
      View in: PubMed
    63. Naganuma M, Sakuraba A, Hisamatsu T, Ochiai H, Hasegawa H, Ogata H, Iwao Y, Hibi T. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. Inflamm Bowel Dis. 2008 Sep; 14(9):1259-64. PMID: 18393375.
      View in: PubMed
    64. Komiyama T, Yajima T, Kubota R, Iwao Y, Sakuraba A, Funakoshi S, Negishi K, Minami I, Tanaka Y, Mae H, Hibi T. Lower doses of 6-mercaptopurine/azathioprine bring enough clinical efficacy and therapeutic concentration of erythrocyte 6-mercaptopurine metabolite in Japanese IBD patients. J Crohns Colitis. 2008 Dec; 2(4):315-21. PMID: 21172230.
      View in: PubMed
    65. Kamada N, Hisamatsu T, Okamoto S, Chinen H, Kobayashi T, Sato T, Sakuraba A, Kitazume MT, Sugita A, Koganei K, Akagawa KS, Hibi T. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest. 2008 Jun; 118(6):2269-80. PMID: 18497880.
      View in: PubMed
    66. Sakuraba A, Sato T, Naganuma M, Morohoshi Y, Matsuoka K, Inoue N, Takaishi H, Ogata H, Iwao Y, Hibi T. A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis. J Gastroenterol. 2008; 43(1):51-6. PMID: 18297436.
      View in: PubMed
    67. Takaishi H, Matsuki T, Nakazawa A, Takada T, Kado S, Asahara T, Kamada N, Sakuraba A, Yajima T, Higuchi H, Inoue N, Ogata H, Iwao Y, Nomoto K, Tanaka R, Hibi T. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol. 2008 Jul; 298(5-6):463-72. PMID: 17897884.
      View in: PubMed
    68. Matsuoka K, Iwao Y, Mori T, Sakuraba A, Yajima T, Hisamatsu T, Okamoto S, Morohoshi Y, Izumiya M, Ichikawa H, Sato T, Inoue N, Ogata H, Hibi T. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol. 2007 Feb; 102(2):331-7. PMID: 17156136.
      View in: PubMed
    69. Sato T, Nakai T, Tamura N, Okamoto S, Matsuoka K, Sakuraba A, Fukushima T, Uede T, Hibi T. Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut. 2005 Sep; 54(9):1254-62. PMID: 16099792.
      View in: PubMed
    70. Hibi T, Sakuraba A. Is there a role for apheresis in gastrointestinal disorders? Nat Clin Pract Gastroenterol Hepatol. 2005 May; 2(5):200-1. PMID: 16265186.
      View in: PubMed
    71. Matsuoka K, Inoue N, Sato T, Okamoto S, Hisamatsu T, Kishi Y, Sakuraba A, Hitotsumatsu O, Ogata H, Koganei K, Fukushima T, Kanai T, Watanabe M, Ishii H, Hibi T. T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease. Gut. 2004 Sep; 53(9):1303-8. PMID: 15306590.
      View in: PubMed
    72. Naganuma M, Funakoshi S, Sakuraba A, Takagi H, Inoue N, Ogata H, Iwao Y, Ishi H, Hibi T. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis. 2004 May; 10(3):251-7. PMID: 15290920.
      View in: PubMed
    73. Sato T, Kanai T, Watanabe M, Sakuraba A, Okamoto S, Nakai T, Okazawa A, Inoue N, Totsuka T, Yamazaki M, Kroczek RA, Fukushima T, Ishii H, Hibi T. Hyperexpression of inducible costimulator and its contribution on lamina propria T cells in inflammatory bowel disease. Gastroenterology. 2004 Mar; 126(3):829-39. PMID: 14988837.
      View in: PubMed
    74. Hibi T, Ogata H, Sakuraba A. Animal models of inflammatory bowel disease. J Gastroenterol. 2002; 37(6):409-17. PMID: 12108674.
      View in: PubMed
    Sakuraba's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _